OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 76 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2014. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.

Quarter-by-quarter ownership
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2014$204,000,000
-85.6%
50,000
-84.3%
0.00%
-85.2%
Q2 2013$1,419,000,000318,1910.03%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q2 2014
NameSharesValueWeighting ↓
Broadfin Capital, LLC 8,951,169$54,871,0003.38%
Virtus ETF Advisers LLC 103,807$636,0001.75%
BKS ADVISORS, LLC 291,150$1,785,0000.92%
Piermont Capital Management Inc. 363,549$2,229,0000.71%
TUDOR INVESTMENT CORP ET AL 2,370,760$14,532,0000.41%
SEARLE & CO. 60,000$349,0000.34%
TURNER INVESTMENTS LLC 252,785$1,550,0000.32%
RICE HALL JAMES & ASSOCIATES, LLC 891,672$5,466,0000.31%
Phocas Financial Corp. 635,333$3,895,0000.30%
TFS CAPITAL LLC 398,283$2,441,0000.26%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders